Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Fasting
Interventions: Desloratadine; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Atrial Fibrillation, Paroxysmal or Persistent, Atrial Fibrillation and Flutter, Atrial Flutter Typical
Interventions: VARIPULSE™ catheter ablation; Device
Lead sponsor: Vivek Reddy; Other
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Iron Deficiency
Interventions: Iron sucrose; Drug
Lead sponsor: The Guthrie Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Sayre, Pennsylvania

Conditions: HIV-1-infection
Interventions: PrEPsmart mobile app, Truvada; Device · Drug
Lead sponsor: Public Health Foundation Enterprises, Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent Ovarian Cancer
Interventions: CPI-0209, carboplatin; Drug
Lead sponsor: Lan Coffman; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV, AIDS, Fetal Alcohol Syndrome, Alcohol Related Neurodevelopmental Disorder
Interventions: Opt-in or Opt-out testing, Focus Group; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Propionic Acidemia, Type I and/or Type II, Methylmalonic Acidemia, Carbamoyl-Phosphate Synthase I Deficiency Disease, Ornithine Carbamoyltransferase Deficiency
Interventions: Carbaglu, Placebo; Drug
Lead sponsor: Mendel Tuchman; Other
Eligibility: 1 Week to 99 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 6 more

Conditions: HIV Prevention Program, Opioid-use Disorder
Interventions: iRaPID, Standard of Care; Behavioral · Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: AG-348, [13C6]AG-348; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II
Interventions: Durvalumab, the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30), COPD Assessment Test (CAT), Modified Medical Research Council (mMRC) dyspnea scale; Drug · Other · Diagnostic Test
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Mallet Fracture, Metacarpal Fracture, Metacarpal Neck Fracture, Distal Radius Fracture, Radial Head Fracture
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes Mellitus
Interventions: Bionic Pancreas, Usual Care; Device · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Krill Oil; Dietary Supplement
Lead sponsor: Aker BioMarine Human Ingredients AS; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Saint Charles, Missouri • Fargo, North Dakota

Conditions: SARS-CoV-2, Influenza A, Influenza B, COVID-19
Interventions: LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B; Diagnostic Test
Lead sponsor: LumiraDx UK Limited; Industry
Eligibility: Not listed
Enrollment: 716 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 10
States / cities: Garden Grove, California • Lomita, California • DeLand, Florida + 6 more

Conditions: Cardiovascular Diseases, Coronary Disease, Heart Diseases
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 30 Years to 59 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19 Respiratory Infection
Interventions: The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2.; Diagnostic Test
Lead sponsor: Abbott Rapid Diagnostics Jena GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Chicago, Illinois • Durham, North Carolina • Powdersville, South Carolina + 2 more

Conditions: Healthy
Interventions: Lamotrigine, Lamictal®; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 20 Years to 44 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Quadrangle Drive, North Carolina

Conditions: Healthy Volunteers
Interventions: TAK-227; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Anxiety Disorder
Interventions: Thinking Skills for Work Program, Supported Employment; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Chicago, Illinois • Manchester, New Hampshire

Conditions: COVID-19
Interventions: Text-Messaging (TM), Conversational Agent (CA), Patient Navigation (PN); Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 2,117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Thermal Burn
Interventions: Celution Device; Device
Lead sponsor: Cytori Therapeutics; Industry
Eligibility: Up to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Phoenix, Arizona • San Diego, California • Galveston, Texas + 1 more

Conditions: Distracted Driving, Injury Prevention, Behavioral Economics
Interventions: Driving Tips, Standard Feedback, Assigned Focus Area Feedback, Study Dashboard (Standard), Study Dashboard (focused), UBI-like Behavioral Incentive, Sef-Chosen Focus Area Feedback; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1,449 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heart Failure With a Preserved Ejection Fraction, Heart Failure, Diastolic, Chronotropic Incompetence
Interventions: Rate adaptive atrial pacing using a dual-chamber pacemaker, Pacemaker system will be implanted but set to Pacing Off.; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Myelodysplastic Syndrome, MDS, Trisomy 8
Interventions: rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more

Search by objective public record fields.

Bioavailability Study of Dr. Reddy's Desloratadine Tablets, 5 mg Under Fasting Conditions.

Versatility of a Circular Multielectrode Catheter in the Individualized Recognition & Treatment of Atrial Fibrillation and Related Arrhythmias Using Pulsed Field Energy

The Safety of a High-Dose, Rapid Infusion of Iron Sucrose

PrEPsmart 2-1-1 Pilot

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Expansion to Interdisciplinary HIV Prevention in Women

Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia

Testing of the Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs Program

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Optional Follow-up Visits for Common, Low-risk Arm Fractures

The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes

Study to Investigate the Effects of Krill Oil on Fasting Serum Triglycerides

POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.

Comparison of Two Methods to Diagnose Coronary Artery Disease

BinaxNow COVID-19 IgG Rapid Test Device and Antibody Self Test

Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition

A Study of TAK-227 in Healthy Adults

Thinking Skills for Work in Severe Mental Illness

SCALE-UP Utah II: Community-Academic Partnership to Address COVID-19 Conversational Agent Study

Feasibility of Obtaining ADRCs From Discarded Thermal Burn Eschar Tissue Using Investigational Celution® System

A Randomized Field Trial of Smartphone-based Feedback to Encourage Safe Driving

Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome